DrugPatentWatch Database Preview
Pazopanib hydrochloride - Generic Drug Details
What are the generic sources for pazopanib hydrochloride and what is the scope of pazopanib hydrochloride patent protection?
Pazopanib hydrochloride
is the generic ingredient in one branded drug marketed by Novartis Pharms Corp and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Pazopanib hydrochloride has forty patent family members in twenty-five countries.
There are five drug master file entries for pazopanib hydrochloride. One supplier is listed for this compound.
Summary for pazopanib hydrochloride
| International Patents: | 40 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 5 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 69 |
| Clinical Trials: | 265 |
| Patent Applications: | 99 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | pazopanib hydrochloride at DailyMed |
Pharmacology for pazopanib hydrochloride
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Protein Kinase Inhibitors Cytochrome P450 3A4 Inhibitors Cytochrome P450 2D6 Inhibitors Cytochrome P450 2C8 Inhibitors |
Synonyms for pazopanib hydrochloride
| 33Y9ANM545 |
| 5-((4-((2,3-DIMETHYL-2H-INDAZOL-6-YL)(METHYL)AMINO)PYRIMIDIN-2-YL)AMINO)-2-METHYLBENZENESULFONAMIDE HYDROCHLORIDE |
| 5-((4-((2,3-Dimethyl-2H-indazol-6-yl)methylamino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide monohydrochloride |
| 5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]-2-pyrimidinyl}amino)-2-methylbenzenesulfonamide Hydrochloride |
| 5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide hydrochloride |
| 5-({4-[(2,3-dimethylindazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide hydrochloride |
| 5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide hydrochloride |
| 5-[[4-[(2,3-dimethyl-6-indazolyl)-methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide hydrochloride |
| 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide hydrochloride |
| 635702-64-6 |
| 786034 HYDROCHLORIDE |
| A834417 |
| AC-24726 |
| AK163181 |
| AKOS015958593 |
| AM20090655 |
| AN-16933 |
| Armala |
| ARMALA HYDROCHLORIDE |
| AX8294838 |
| BCP9001052 |
| Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-, monohydrochloride |
| Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-, hydrochloride (1:1) |
| C21H23N7O2S.HCl |
| CHEBI:71217 |
| CHEMBL1201733 |
| CS-0126 |
| D05380 |
| DTXSID70212956 |
| EX-A956 |
| FT-0687642 |
| GSK-786034 |
| GW 786034 |
| GW 786034 HYDROCHLORIDE |
| GW-786034B |
| GW786034B |
| GW786034GW786034 |
| HY-12009 |
| KB-79770 |
| KS-000003E0 |
| KS-1458 |
| MFCD12546138 |
| MLS004774147 |
| MolPort-009-679-403 |
| MQHIQUBXFFAOMK-UHFFFAOYSA-N |
| NSC-737754 |
| NSC737754 |
| Patorma |
| Pazopanib (Hydrochloride) |
| pazopanib HCl |
| Pazopanib HCl (GW786034 ) |
| Pazopanib HCl (GW786034 HCl) |
| Pazopanib hydrochloride (JAN/USAN) |
| Pazopanib hydrochloride [USAN:JAN] |
| pazopanib monohydrochloride |
| PB31655 |
| S1035 |
| SC-90768 |
| SCHEMBL159487 |
| SMR003500790 |
| ST24048877 |
| SYN1058A |
| UNII-33Y9ANM545 |
| Votrient |
| Votrient (TN) |
| VOTRIENT HYDROCHLORIDE |
| W-5532 |
| X3177 |
US Patents and Regulatory Information for pazopanib hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Novartis Pharms Corp | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Novartis Pharms Corp | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Novartis Pharms Corp | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Novartis Pharms Corp | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Novartis Pharms Corp | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Novartis Pharms Corp | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for pazopanib hydrochloride
| Country | Document Number | Estimated Expiration |
|---|---|---|
| China | 1307173 | ➤ Sign Up |
| Hungary | 0400691 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 02059110 | ➤ Sign Up |
| Norway | 20032831 | ➤ Sign Up |
| Australia | 2002246723 | ➤ Sign Up |
| Slovenia | 1343782 | ➤ Sign Up |
| Japan | 2004517925 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for pazopanib hydrochloride
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C/GB10/032 | United Kingdom | ➤ Sign Up | PRODUCT NAME: PAZOPANIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; REGISTERED: UK EU 1/10/628/001 20100614; UK EU 1/10/628/002 20100614; UK EU 1/10/628/003 20100614; UK EU 1/10/628/004 20100614 |
| 2010 00024 | Denmark | ➤ Sign Up | PRODUCT NAME: PAZOPANIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER HYDROCLORID |
| /2010 | Austria | ➤ Sign Up | PRODUCT NAME: PAZOPANIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/10/628/001 - EU/1/10/628/004 20100614 |
| 710 | Luxembourg | ➤ Sign Up | 91710, EXPIRES: 20250614 |
| 00456 | Netherlands | ➤ Sign Up | PRODUCT NAME: PAZOPANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT, IN HET BIJZONDER PAZOPANIB HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/10/628/001-004 20100614 |
| C025/2010 | Ireland | ➤ Sign Up | SPC025/2010: 20110401, EXPIRES: 20250613 |
| 9 | Finland | ➤ Sign Up | |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Follow DrugPatentWatch: